| REPORT ATTRIBUTE |
DETAILS |
| Historical Period |
2019-2022 |
| Base Year |
2023 |
| Forecast Period |
2024-2032 |
| Continuous Glucose Monitoring (CGM) Device Market Size 2024 |
USD 11,705 Million |
| Continuous Glucose Monitoring (CGM) Device Market, CAGR |
24.9% |
| Continuous Glucose Monitoring (CGM) Device Market Size 2032 |
USD 69,321.97 Million |
Market Overview:
The Continuous Glucose Monitoring (CGM) Device Market size is poised to grow from USD 11,705 million in 2024 to USD 69,321.97 million by 2032, at a compound annual growth rate (CAGR) of 24.9% during the forecast period 2024-2032.
The market’s rapid growth is driven by the increasing global prevalence of diabetes and heightened awareness of effective diabetes management. Rising demand for minimally invasive and non-invasive glucose monitoring technologies has propelled the adoption of CGM devices. Advancements in sensor technology, integration with smartphones and wearable devices, and the introduction of AI-driven analytics further enhance the functionality and appeal of these systems. Additionally, the increasing focus on preventive healthcare and early diagnosis fuels demand across all age groups. The National Institute of Diabetes and Digestive and Kidney Diseases reported that 38.4 million people (11.6% of the population) had diabetes in 2022, with 38.1 million being adults, highlighting the critical need for continuous glucose monitoring solutions.
North America dominates the CGM device market, accounting for the largest share in 2024, driven by high diabetes prevalence, advanced healthcare infrastructure, and strong reimbursement frameworks. Europe follows closely, supported by increasing awareness, favorable healthcare policies, and a growing focus on technological innovation The Asia-Pacific region is anticipated to witness the fastest growth, fueled by rising diabetes cases, urbanization, and increased healthcare spending in countries like China and India. Emerging markets in Latin America and the Middle East & Africa are also gaining traction, driven by improving healthcare infrastructure and rising awareness of advanced diabetes management solutions.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research!
Download Sample
Market Insights:
- The CGM device market is projected to grow from USD 11,705 million in 2024 to USD 69,321.97 million by 2032, with a strong CAGR of 24.9%.
- The increasing global burden of diabetes drives the adoption of CGM devices for effective glucose management.
- Integration with smartphones, wearable devices, and AI-driven analytics enhances CGM device functionality and usability.
- Rising demand for minimally invasive glucose monitoring technologies fuels market expansion.
- North America leads the market, supported by advanced healthcare infrastructure and favorable reimbursement policies.
- The Asia-Pacific region exhibits the fastest growth due to rising diabetes cases and increasing healthcare spending in countries like China and India.
- High costs of CGM devices and limited awareness in low-income regions may hinder widespread adoption.
Market Drivers:
Rising Diabetes Prevalence:
The increasing incidence of diabetes globally drives substantial demand for CGM devices. For instance, according to recent WHO data, diabetes affects 422 million people worldwide, with annual mortality rates exceeding 1.5 million. The growing diabetic population, particularly in developing regions where diagnosis rates have increased by 35% since 2019, necessitates advanced glucose monitoring solutions. Type 2 diabetes accounts for approximately 95% of all diagnosed cases, with a 50% increase in early-onset diabetes among young adults.
Technological Advancements:
Innovation in CGM technology significantly enhances market growth. For instance, modern devices achieve accuracy rates of 95-99% with Mean Absolute Relative Difference (MARD) values below 10%. Latest sensors demonstrate extended wear time of up to 180 days, while maintaining continuous glucose readings every 5 minutes with transmission ranges up to 20 feet. these advanced systems reduce fingerstick calibrations by 85% compared to traditional monitoring methods.
Home Healthcare Adoption:
The shift toward home-based care drives CGM device adoption. For instance, remote monitoring capabilities have increased patient compliance by 65%, with 82% of users reporting improved glucose control. Studies indicate that CGM use reduces HbA1c levels by an average of 1.0% within three months of adoption, while decreasing hypoglycemic episodes by 40%. in March 2024, Dexcom received FDA clearance for Stelo, a non-prescription CGM device specifically designed for individuals with Type 2 diabetes who don’t use insulin, exemplifying the industry’s move towards more accessible and user-friendly devices.
Healthcare Infrastructure Development:
The expansion of healthcare infrastructure and increasing healthcare expenditure support market growth. annual diabetes-related healthcare costs average $16,752 per person in developed nations. The implementation of CGM systems has shown to reduce hospital admissions by 25% and decrease emergency room visits by 30% among regular users, demonstrating significant cost-saving potential in diabetes management. For instance, in 2023, UnitedHealthcare, a major health insurance company in the United States, began providing coverage for CGMs for people with type 2 diabetes who require insulin, making the technology more accessible to a broader patient population.
Market Trends:
Advanced Sensor Technology:
The evolution of sensor technology marks significant advancement in CGM devices. For instance, modern sensors achieve accuracy rates of 95-99% with Mean Absolute Relative Difference (MARD) values below 10%, providing comprehensive glucose monitoring. The latest devices like the Freestyle Libre 3 represent the smallest CGM sensors to date, with a size of just two stacked U.S. pennies, and offer minute-to-minute glucose readings that stream directly to the user’s compatible smartphone. Meanwhile, Eversense E3’s implantable technology extends wear time to 180 days, revolutionizing long-term monitoring capabilities.
Integration with Automated Insulin Delivery:
The integration of CGM systems with automated insulin delivery (AID) systems represents a revolutionary advancement in diabetes management. these closed-loop control systems, also known as “artificial” or “bionic” pancreas, automatically adjust insulin delivery based on real-time glucose data. The systems maintain precise control over blood glucose levels through automated collection and analysis of continuous glucose data. For instance, the Eversense E3 system has been shown to improve glucose control without increasing hypoglycemia compared with standard insulin therapy, with a 35 percentage point increase in time spent in target glucose range.
Mobile Technology Integration:
The increasing connectivity between CGM devices and mobile platforms enhances user experience and data management capabilities. these systems provide both retrospective and real-time information to detect hypoglycemic and hyperglycemic excursions, while predicting impending hypoglycemia. The technology enables detailed analysis of glucose patterns, including diurnal variations, meal effects, and exercise impacts. For instance, the FreeStyle Libre 3 system integrates with the FreeStyle Libre 3 iOS and Android mobile apps, allowing users to view their glucose levels in real time, track their glucose history and trends, and set up optional alarms plus notifications to help them be alerted of serious medical events like hypoglycemia.
Expanded User Base:
CGM technology adoption has expanded beyond traditional diabetic patients to include athletes and fitness enthusiasts. Olympic athletes are increasingly using CGMs to optimize training, nutrition, and athletic performance. The technology enables athletes to fine-tune their nutrition and training schedules through real-time glucose monitoring, while providing valuable insights for performance optimization. For instance, the Abbott Libre Sense Glucose Sport Biosensor, based on FreeStyle Libre technology, is now CE marked for athletes, making it the world’s first glucose sport biosensor.
Market Challenges Analysis:
Cost and Insurance Coverage Barriers:
The substantial financial burden associated with CGM devices presents a significant market barrier. For instance, according to the Centers for Medicare & Medicaid Services (CMS), strict eligibility criteria include requirements for blood glucose monitoring four times daily and mandatory face-to-face clinic visits every six months. These requirements, coupled with high device and supply costs, create accessibility challenges, particularly affecting individuals without private insurance coverage. For instance, a study by the National Institute of Diabetes and Digestive and Kidney Diseases reported that 38.4 million people (11.6% of the population) had diabetes in 2022, with 38.1 million being adults, highlighting the critical need for continuous glucose monitoring solutions. Additionally, a survey by the Journal of Diabetes Science and Technology revealed that all respondents agreed CGM enhances quality of life and has the potential to optimize diabetes management, yet cost remains a significant barrier to adoption.
Technical and Usage Limitations:
Device accuracy and reliability issues pose ongoing challenges for widespread adoption. For instance, the Food and Drug Administration (FDA) notes specific limitations regarding insulin dosing applications and usage in hospital settings. Users report technical challenges including sensor calibration requirements, periodic replacements, and data uploading complexities, affecting the overall user experience. For instance, a study by the Journal of Diabetes Science and Technology found that while CGM devices may lead to improved glycemic control, there were many issues with the technology which often led to patient dissatisfaction and discontinued use. Among the top reasons cited was varying levels of accuracy between sensors, particularly on the first and last day of wear, leading to 59% of participants stopping use of their CGM device for at least one month.
Healthcare Professional Integration:
The lack of standardized training and implementation protocols creates significant adoption barriers. For instance, healthcare providers often face challenges in data interpretation and patient education, leading to potential gatekeeping of technology access. The American Diabetes Association recommends robust training programs, yet unclear guidelines regarding training responsibility create additional implementation hurdles. For instance, a study by the Journal of Diabetes Science and Technology revealed that all respondents agreed CGM enhances quality of life and has the potential to optimize diabetes management, yet lack of education and support can cause issues for people using CGMs. Additionally, a survey by the Journal of Diabetes Science and Technology found that 20% of the specialty professionals surveyed were eager and ready to support CGM in their clinical practice, 40% remained cautious, and 39% indicated that they were not yet ready to integrate CGM into the clinical paradigm, citing significant barriers that were both personal and structural.
Device-Specific Challenges:
Physical and operational limitations affect user acceptance and continued usage. For instance, users report issues such as skin irritation, alarm fatigue, and adhesive integrity problems. The integration with Automated Insulin Delivery (AID) systems presents additional complexities, including calibration requirements and system maintenance needs. For instance, a study by the Journal of Diabetes Science and Technology found that while CGM devices may lead to improved glycemic control, there were many issues with the technology which often led to patient dissatisfaction and discontinued use. These technical challenges particularly affect younger patients and those newly diagnosed with diabetes, impacting long-term adoption rates. For instance, a study by the Journal of Diabetes Science and Technology found that 25% of participants found alarms on low readings useful while 10% considered alarms for high reading as a major advantage, yet alarm fatigue was a common reason for discontinuation.
Market Opportunities:
The Continuous Glucose Monitoring (CGM) Device Market offers immense growth opportunities driven by the increasing global prevalence of diabetes and the rising need for effective glucose management solutions. The shift toward preventive healthcare and early diagnosis highlights the importance of CGM devices, which provide real-time data and actionable insights to patients and healthcare professionals. Advancements in sensor technologies and seamless integration with smartphones and wearable devices enhance user convenience and accuracy, making CGM systems indispensable tools in diabetes management. Additionally, the growing emphasis on personalized medicine presents an opportunity for CGM manufacturers to tailor devices to individual needs, improving patient outcomes and satisfaction.
Emerging markets in the Asia-Pacific, Latin America, and Middle East & Africa regions hold substantial potential due to the increasing prevalence of diabetes, rapid urbanization, and improving healthcare infrastructure. Governments and healthcare organizations in these regions are focusing on diabetes awareness campaigns and accessibility to advanced treatment options, creating favorable conditions for CGM device adoption. Moreover, the rise of telemedicine and remote patient monitoring solutions provides new avenues for growth, as CGM devices can seamlessly integrate with digital health platforms. Companies that prioritize innovation, affordability, and market-specific strategies are well-positioned to capitalize on these opportunities, ensuring sustained growth and expanded global reach.
Market Segmentation Analysis:
By Component
The market is further segmented by components, such as liquid chromatography consumables and gas chromatography consumables. Liquid chromatography consumables are used in systems that separate compounds based on their interactions with a liquid mobile phase, while gas chromatography consumables are used in systems that separate compounds based on their interactions with a gas mobile phase.
By End User
The market is categorized by end users, including pharmaceuticals, biotechnology, chemicals, environmental testing, food & beverage, and others. Pharmaceuticals and biotechnology industries use chromatography consumables for drug development and quality control. The chemicals industry employs these consumables for process monitoring and research. Environmental testing utilizes chromatography consumables for pollution analysis, while the food & beverage industry uses them for ensuring product safety and quality.
Segmentations:
By Component:
- Transmitters
- Sensors
- Receivers
By End-Use:
- Hospitals
- Home Care
- Other End-uses
By Region:
- North America
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Regional Analysis:
North America
North America holds the largest market share, accounting for 40% of the global market in 2024. This dominance is attributed to the high prevalence of diabetes, advanced healthcare infrastructure, and robust reimbursement policies in the United States and Canada. For instance, the Centers for Disease Control and Prevention (CDC) National Diabetes Statistics Report 2022 estimated that more than 130 million adults live with diabetes or prediabetes in the United States. The growing awareness of preventive healthcare and early diabetes management further accelerates CGM adoption in the region. For instance, the Centre for Health Care Strategies for Medicaid agencies has highlighted the benefits of CGM use for all people who are insulin-treated with an insulin pump or multiple daily insulin injections. Technological advancements, such as integration with wearables and smartphones, are widely embraced, enhancing user convenience and driving market growth. For instance, Abbott introduced a new, lower-priced category with Libre, at around USD 75 to USD 150 each month (two sensors that last 14 days each), to lower the cost burden of diabetic patients in the United States. Major players in the CGM industry also focus heavily on product development and clinical trials in North America, reinforcing the region’s leading position.
Europe
Europe represents 30% of the market share, supported by increasing healthcare expenditure and strong awareness of advanced diabetes management solutions. Countries like Germany, the United Kingdom, and France are leading contributors, driven by favorable healthcare policies and the rising adoption of innovative medical devices. For instance, the European Green Deal aims to reduce industrial waste by 50% by 2030, which could impact the production and disposal of CGM devices. The region’s focus on technological innovation and patient-centered care aligns with the growing demand for minimally invasive and real-time glucose monitoring systems. For instance, the European Commission reported that industrial emissions decreased by 14% between 2019 and 2023, thanks to the adoption of cleaner production technologies. Additionally, government-led initiatives to tackle the diabetes epidemic further bolster market growth in Europe. For instance, the German Center for Diabetes Research (DZD) conducts extensive scientific research to develop effective prevention and treatment measures to halt the emergence or progression of diabetes.
Asia-Pacific
Asia-Pacific is the fastest-growing region currently holding 20% of the market share. The rising prevalence of diabetes in countries like China, India, and Japan, coupled with increasing urbanization and disposable incomes, fuels the demand for CGM devices. For instance, China dominates around 56% of the Asia-Pacific Insulin Infusion Pump Market among the Asia-Pacific countries, mainly due to the high diabetes prevalence in this country. Governments in these countries are actively promoting diabetes awareness and early detection campaigns, creating a favorable environment for market expansion. For instance, the National Bureau of Statistics of China, MOH (China), in 2021, reported that China’s expenditure on health and hygiene was Yuan 1,920.5 billion (USD 263.32 billion). The region also benefits from improving healthcare infrastructure and growing investments in digital health solutions, which enhance accessibility to advanced CGM technologies. For instance, in March 2022, Abbott announced that it received expanded reimbursement coverage in Japan for the FreeStyle Libre system.
Latin America and the Middle East & Africa
Latin America and the Middle East & Africa collectively account for 10% of the market share, fueled by improving healthcare infrastructure and rising awareness of diabetes management. In Latin America, countries like Brazil and Mexico are experiencing increased adoption of CGM devices due to growing healthcare investments and a rising focus on chronic disease management. For instance, Brazil implemented a set of reforms to improve the distribution of doctors, develop new forms of the service organization, introduce new financing models, and implement a range of quality improvement initiatives and policy frameworks to overcome risk factors such as obesity. The Middle East & Africa region sees growth driven by increasing diabetes prevalence and the adoption of advanced medical technologies in affluent urban areas. For instance, the International Diabetes Federation (IDF) reported that the number of adults in South-East Asia (SEA) with diabetes is expected to rise from 90 million in 2021 to 113 million in 2030 and 152 million in 2045.
Key Player Analysis:
- Abbott Laboratories
- Dexcom, Inc.
- Medtronic plc
- Senseonics Holdings, Inc.
- Hoffmann-La Roche Ltd
- Ascensia Diabetes Care Holdings AG
- LifeScan, Inc.
- Menarini Diagnostics S.r.l.
- Ypsomed AG
- Medtrum Technologies Inc.
Competitive Analysis:
The Continuous Glucose Monitoring Device market demonstrates intense competition among established manufacturers, with key players like Medtronic Plc, Dexcom, Inc., Abbott Laboratories, and Senseonics Holdings leading the industry. For instance, North America dominates with the largest market share, valued at USD 5.6 billion in 2024, driven by the high prevalence of diabetes and advanced healthcare infrastructure. The competitive landscape is characterized by continuous product innovation and strategic developments, exemplified by Dexcom’s FDA clearance for Stelo, their over-the-counter CGM device for Type 2 diabetes patients not using insulin. For instance, Stelo is designed for individuals aged 18 and older who do not require insulin therapy, providing a user-friendly option for approximately 25 million people in the U.S. living with Type 2 diabetes. Companies differentiate themselves through technological advancements, particularly in sensor accuracy and user experience, with modern devices achieving Mean Absolute Relative Difference (MARD) values below 10%. For instance, Dexcom’s G7 system requires no fingerstick calibration and offers real-time glucose data every five minutes. The market’s dynamics are further shaped by expanding insurance coverage and the integration of artificial intelligence and machine learning capabilities, with the sensors segment growing at 13.4% annually. For instance, Abbott’s FreeStyle Libre system has gained immense popularity due to its simplicity, featuring optional real-time alarms to enhance user engagement and safety.
Recent Developments:
- June 2024 Abbott received FDA clearance for two new over-the-counter CGM systems – Lingo and Libre Rio. Libre Rio becomes Abbott’s first over-the-counter CGM system for people with Type 2 diabetes who don’t use insulin, featuring a measurement range of 40-400 mg/dL.
- March 2024 Dexcom launched Dexcom ONE+, their latest CGM system in multiple European countries including Spain, Belgium, and Poland. The system incorporates best-in-class sensor technology with enhanced features based on user and healthcare professional feedback.
- December 2024 Menarini Diagnostics entered an exclusive distribution agreement with Sinocare for their 3rd Generation CGM System, gaining rights to distribute in more than 20 European jurisdictions.
- November 2024 Senseonics Holdings received FDA approval for Eversense 365 as an integrated CGM system for people with Type 1 and Type 2 diabetes. The system represents the world’s first and only 365-day CGM device.
- September 2023 Medtronic received CE Mark approval for their new Simplera CGM, featuring an all-in-one disposable design that is 50% smaller than its previous generation, with a simplified two-step insertion process.
Market Concentration & Characteristics:
The Continuous Glucose Monitoring (CGM) Device Market is moderately concentrated, with a few dominant players leading innovation and market penetration. Companies such as Abbott Laboratories, Dexcom, Inc., and Medtronic plc hold substantial market shares due to their extensive product portfolios, advanced technologies, and global distribution networks. The market is characterized by rapid technological advancements, including minimally invasive and non-invasive solutions, integration with smartphones and wearable devices, and AI-powered analytics for personalized diabetes management. While large players focus on continuous innovation and product differentiation, smaller companies are gaining traction by offering cost-effective and region-specific solutions. Challenges such as high device costs and limited awareness in certain regions are gradually being mitigated by government initiatives, increasing healthcare expenditure, and improving reimbursement policies. This dynamic landscape ensures steady growth, driven by rising diabetes prevalence and an emphasis on preventive healthcare.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Report Coverage:
The research report offers an in-depth analysis based on Component, End-Use, and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook:
- Rising global prevalence of diabetes will continue to drive the demand for CGM devices as essential tools for effective disease management.
- Advancements in minimally invasive and non-invasive technologies will enhance patient comfort and broaden the adoption of CGM systems.
- Integration of CGM devices with wearable technologies and smartphones will provide real-time monitoring and data analytics for improved glycemic control.
- AI-powered analytics and predictive algorithms will enable personalized treatment plans and proactive diabetes management.
- Increasing focus on preventive healthcare and early diagnosis will expand the use of CGM devices among at-risk populations.
- Emerging markets, particularly in Asia-Pacific and Latin America, will offer significant growth opportunities due to rising diabetes cases and improving healthcare infrastructure.
- Government initiatives and favorable reimbursement policies in developed regions will support the widespread adoption of CGM systems.
- The rise of telemedicine and remote patient monitoring solutions will drive demand for CGM devices that integrate with digital health platforms.
- Ongoing innovations in sensor technology will enhance device accuracy, durability, and affordability, making CGM systems accessible to a broader audience.
- Collaborations between healthcare providers and technology companies will accelerate the development of advanced solutions, ensuring sustained market growth.
